Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis.
Saved in:
| Title: | Osimertinib plus anlotinib for advanced NSCLC with acquired EGFR T790M mutation: results from a multicenter phase II study with ctDNA analysis. |
|---|---|
| Authors: | Wang, Xinyue1 (AUTHOR), Li, Zhaona2 (AUTHOR), Wang, Liuchun1 (AUTHOR), Liang, Yan1 (AUTHOR), Huang, Chun1 (AUTHOR), Chen, Peng1 (AUTHOR), Huang, Dingzhi1 (AUTHOR), Song, Xia3 (AUTHOR), Ding, Cuimin4 (AUTHOR) wjwdcm@sina.com, Wang, Changli5 (AUTHOR) wangchangli@tjmuch.com, Jiang, Richeng1,6 (AUTHOR) jiangricheng@tjmuch.com |
| Source: | BMC Medicine. 4/15/2025, Vol. 23 Issue 1, p1-11. 11p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
